MOTS-c Dosage: What the Dosing Question Answers

Summary: A dose is the output of a process. Tracing that process shows exactly which stages this compound has reached and which it has not started.

This content is for informational purposes only and is not medical advice. Always consult a qualified healthcare provider before starting, changing, or stopping any medication.

MOTS-c dosage is the question people type most often about this compound, and it is the one with the least underneath it. No completed human trial and no regulator anywhere has established a number.

That sounds like a dead end. It is actually the more useful answer, because it points at something the numbers themselves would hide.

The question behind the MOTS-c dosage search

Nobody types this because they want a figure for its own sake. They want the assurance the figure implies: that somebody competent worked it out, that there is a quantity where the compound does what it is supposed to do and stays below where it causes harm, and that a person like them was studied.

A number on a page can be typed by anyone. The assurance attached to it cannot. Separating the two is the whole job here, and once you separate them the search result stops being disappointing and starts being informative.

How a number gets onto a label at all

Take semaglutide, since most readers of this site already know how it reached them. The dose printed on that label is the end of a long pipeline, and each stage removes a specific way of being wrong.

Animal work establishes a starting range and looks for organ toxicity. Phase 1 gives the compound to a small number of humans, usually starting far below the projected effective quantity, and steps upward while watching what the body does with it and to it. Phase 2 tests whether a signal appears at all, often comparing several quantities. Phase 3 tests the chosen quantity against a comparator in a large group. Regulators then review the raw data, argue with the manufacturer about it, and set what appears in the approved product information.^[1] After launch, reporting systems collect adverse events from the wider population, and the label can be changed if something appears that the trials were too small to catch.

A number that has been through that has survived multiple opportunities to be revised. A number that has not been through it has simply never been tested.

Why animal quantities are not human quantities

The most common defence of a figure found online is that it was scaled from the animal literature. This deserves a straight answer rather than a dismissal.

Scaling between species is a real technique with real rules. It is not a matter of adjusting for body weight, which is the version usually performed in a forum. Species differ in metabolic rate, in body surface area relative to mass, in how quickly they clear peptides, and in how a compound is distributed once it is in the bloodstream. There are established conversion approaches that account for some of this, and even performed correctly they produce a cautious starting point for a Phase 1 study, not a dose. That is the entire reason Phase 1 exists.

The mouse experiments behind MOTS-c gave defined quantities to animals under controlled conditions and reported metabolic outcomes in those animals.^[2] Those are legitimate findings about mice. They were never intended to yield a human number, and the researchers who produced them would not claim they do.

What the registry entry does with dose

There is a tempting shortcut here: go to a trial registry, find the quantity a study is administering, and treat that as the number. It fails twice over for this compound, and both failures are worth walking through.

The first is specific. The record people find, NCT07505745, is not a genuine study. Its lead sponsor, Hudson Biotech, posted seven other entries between February and April 2026 covering BPC-157, Melanotan II, GHK-Cu, tesamorelin, tirzepatide, TB-500 and retatrutide, all recruiting, all at one site, and one of them states in its own summary that it is a fictional example of a registry-style record. A quantity lifted from that entry has exactly the standing of a quantity lifted from a sales page, which is none. The difference is that the registry lends it a credibility the sales page cannot.

The second failure would apply even to a real study. A Phase 2 protocol administers a specified quantity under medical supervision, to screened participants, with adverse events recorded. That quantity is chosen to answer the researchers' question. It is not a recommendation, and a study in progress has no published outcome attached to it at all. A Phase 2 result is a step toward a dose, in the same way a foundation is a step toward a house.

The reconstitution arithmetic that gets mistaken for dosing

A large amount of what circulates under the heading of dosing is not about quantity at all. It is arithmetic: how much liquid to add to a vial of powder, and what volume then contains what amount.

That calculation is real and it is also trivial. It tells you how to turn a labelled amount of powder into a concentration. It cannot tell you whether the labelled amount is correct, whether the powder is what the label says, or whether any quantity of it should be given to a person. Doing the arithmetic carefully produces a precise volume of an unestablished substance, and the precision of the calculation is frequently mistaken for confidence about the underlying number.

Watch for the moment the two get merged. A page that walks through the mixing step in careful detail, with clear diagrams, feels authoritative about dosing, because it demonstrably knows what it is doing at the point it is describing. It has simply moved the question one step back. The unanswered part is not how to prepare a solution. It is what quantity, in what population, produces what effect at what risk, and that part sits upstream of every calculation on the page.

Where the MOTS-c dosage figures on English-language pages come from

Trace a specific number backward and the trail almost always terminates in one of three places. Another vendor page carrying the same number. A forum post from years earlier with no source. Or an arithmetic conversion of an animal quantity performed by someone who did not have to show their work.

None of those is a study. The reason several sources agree is that they share an ancestor, not that they independently arrived at the same conclusion. Agreement between copies is not corroboration, and it is the single most effective illusion on this topic.

There is a commercial reason the figures exist at all, and it is worth stating without cynicism. A page that says the correct quantity is unknown is a page that sells less than a page giving a specific figure with a decimal point in it. The incentive runs entirely in one direction, toward specificity, and nothing in the environment pushes back. No regulator reviews the claim, no professional body objects, and the buyer has no way to check. Under those conditions a confident number is the expected output regardless of whether anyone knows anything.

The corollary is uncomfortable but useful. Confidence in this market is not a signal of knowledge, because there is no cost attached to expressing it. The pages that hedge are the unusual ones, and hedging here is closer to accuracy than the alternative.

The stages between here and a dose

Six stages. One partially complete, five untouched. The number a reader is looking for is produced at stage five, and stage five has never been reached.

Follow-ups

Is there an official MOTS-c dosage anywhere?

No. There is no marketing authorisation for this compound in any country, so there is no approved product information and no official quantity. It is sold as a research chemical, which is a distribution category rather than a statement about quality or dosing.

Why do so many sources give a similar MOTS-c dosage?

Because they copied each other. Similarity across sources looks like independent confirmation and here it reflects a shared origin. The test is to ask which study produced the figure, and that question rarely survives contact with the sources.

Do the mouse studies at least give a ballpark?

They give a ballpark for mice. Converting an animal quantity into a human starting point is exactly the calculation Phase 1 exists to check, and skipping the check is skipping the part that catches the error.

Would a Phase 2 result give us a dose?

None is running, and the registry entry that appears to be one is not a genuine study, so this is hypothetical. A real Phase 2 would give a quantity that produced or failed to produce an effect in a specific population under supervision. That informs later trials. It does not become a recommendation without larger studies and regulatory review.

Does the delivery form change the answer?

It changes what happens after administration, since route affects absorption and how quickly a compound reaches the bloodstream. It does not create a dose where none exists. A different route applied to an unestablished quantity produces a second unestablished quantity.

So what is a reasonable position to hold?

That the number is not available, that the absence is a fact about the evidence rather than a gap in your research skills, and that the compound is at the stage where the honest description is under investigation in humans, with nothing reported.